Protagonist Therapeutics, a spin-out company from The University of Queensland’s Institute for Molecular Bioscience (IMB), has raised $40 million to begin clinical trials of an oral drug for Inflammatory Bowel Disease.
IMB researchers have been awarded over $10 million from the National Health and Medical Research Council (NHMRC) to investigate pain relief, dengue fever vaccinations and asthma treatments.
